Exact Mass: 277.2536
Exact Mass Matches: 277.2536
Found 107 metabolites which its exact mass value is equals to given mass value 277.2536,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Venlafaxine
Venlafaxine (brand name: Effexor or Efexor) is a bicyclic antidepressant and is usually categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI), but it has been referred to as a serotonin-norepinephrine-dopamine reuptake inhibitor. It works by blocking the transporter reuptake proteins for key neurotransmitters affecting mood, thereby leaving more active neurotransmitter in the synapse. The neurotransmitters affected are serotonin (5-hydroxytryptamine) and norepinephrine (noradrenaline). Additionally, in high doses, it weakly inhibits the reuptake of dopamine. A comparison of adverse event rates in a fixed-dose study comparing venlafaxine 75, 225, and 375 mg/day with placebo revealed a dose dependency for some of the more common adverse events associated with venlafaxine use. The rule for including events was to enumerate those that occurred at an incidence of 5\\% or more for at least one of the venlafaxine groups and for which the incidence was at least twice the placebo incidence for at least one venlafaxine group. Tests for potential dose relationships for these events (Cochran-Armitage Test, with a criterion of exact 2-sided p-value <= 0.05) suggested a dose-dependency for several adverse events in this list, including chills, hypertension, anorexia, nausea, agitation, dizziness, somnolence, tremor, yawning, sweating, and abnormal ejaculation (Wyeth Monograph). Venlafaxine is an effective anti-depressant for many persons; however, it seems to be especially effective for those with treatment-resistant depression. Patients suffering from severe long-term depression typically respond better to venlafaxine than other drugs. However, venlafaxine has been reported to be more difficult to discontinue than other antidepressants. In addition, a September 2004 Consumer Reports study ranked venlafaxine as the most effective among six commonly prescribed antidepressants. However, this should not be considered a definitive finding, since responses to psychiatric medications can vary significantly from individual to individual. A black box warning has been issued with venlafaxine and with other SSRI and SNRI anti-depressants advising of risk of suicide. There is an additional risk if a physician misinterprets patient expression of adverse effects such as panic or akathisia. Careful assessment of patient history and comorbid risk factors such as drug abuse are essential in evaluating the safety of venlafaxine for individual patients. Another risk is serotonin syndrome. This is a serious effect that can be caused by interactions with other drugs and is potentially fatal. This risk necessitates clear information to patients and proper medical history. Venlafaxine is used primarily for the treatment of depression, generalized anxiety disorder, obsessive-compulsive disorder, social anxiety disorder, and panic disorder in adults. It is also used for other general depressive disorders. Although it is not approved for use in children or adolescents, there is considerable information by Wyeth on cautions if prescribed to this age group. Venlafaxine hydrochloride is a prescription antidepressant first introduced by Wyeth in 1993. As of August 2006, generic venlafaxine is available in the United States. CONFIDENCE standard compound; INTERNAL_ID 417; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7277; ORIGINAL_PRECURSOR_SCAN_NO 7275 CONFIDENCE standard compound; INTERNAL_ID 417; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7245; ORIGINAL_PRECURSOR_SCAN_NO 7242 CONFIDENCE standard compound; INTERNAL_ID 417; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7253; ORIGINAL_PRECURSOR_SCAN_NO 7251 CONFIDENCE standard compound; INTERNAL_ID 417; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7306; ORIGINAL_PRECURSOR_SCAN_NO 7304 CONFIDENCE standard compound; INTERNAL_ID 417; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7276; ORIGINAL_PRECURSOR_SCAN_NO 7274 CONFIDENCE standard compound; INTERNAL_ID 417; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7292; ORIGINAL_PRECURSOR_SCAN_NO 7289 D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents CONFIDENCE Parent Substance with Reference Standard (Level 1); INTERNAL_ID 1900 C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants CONFIDENCE standard compound; INTERNAL_ID 8322 CONFIDENCE standard compound; INTERNAL_ID 1502 D049990 - Membrane Transport Modulators
terbutol
CONFIDENCE standard compound; INTERNAL_ID 1079; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10877; ORIGINAL_PRECURSOR_SCAN_NO 10876 CONFIDENCE standard compound; INTERNAL_ID 1079; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10902; ORIGINAL_PRECURSOR_SCAN_NO 10901 CONFIDENCE standard compound; INTERNAL_ID 1079; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10932; ORIGINAL_PRECURSOR_SCAN_NO 10927 CONFIDENCE standard compound; INTERNAL_ID 1079; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10957; ORIGINAL_PRECURSOR_SCAN_NO 10956 CONFIDENCE standard compound; INTERNAL_ID 1079; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10982; ORIGINAL_PRECURSOR_SCAN_NO 10981
Perhexiline
Perhexiline is only found in individuals that have used or taken this drug. It is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis. [PubChem]Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C - Cardiovascular system > C08 - Calcium channel blockers > C08E - Non-selective calcium channel blockers D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
(2R,3S)-1-[(7-Methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol
2-Ethylhexyl 4-(dimethylamino)benzoate
D020011 - Protective Agents > D011837 - Radiation-Protective Agents > D013473 - Sunscreening Agents C1892 - Chemopreventive Agent > C851 - Sunscreen D003879 - Dermatologic Agents D003358 - Cosmetics
venlafaxine
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants CONFIDENCE standard compound; EAWAG_UCHEM_ID 645 D049990 - Membrane Transport Modulators
(E,E,Z)-N-(2-methylpropyl)-2,4,8-tetradecatrienamide|2,4,8-Tetradecatrienoic acid isobutylamide|N-isobutyl-(2E,4E,8Z)-tetradeca-2,4,8-trienamide|N-isobutyl-(2E,4E,8Z)-tetradecatrienamide|tetradeca-2E,4E,8Z-trienoic acid isobutylamide|tetradeca-2t,4t,8c-trienoic isobutyl amide
(+)-1-[6-(beta-Hydroxy-phenaethyl)-1-methyl-[2]piperidyl]-propan-2-ol|(+)-1-[6-(beta-hydroxy-phenethyl)-1-methyl-[2]piperidyl]-propan-2-ol
(+)(Xi)-1-[(2Xi)-cis-6-((Xi)-beta-Hydroxy-phenaethyl)-[2]piperidyl]-butan-2-ol|(+)(Xi)-1-[(2Xi)-cis-6-((Xi)-beta-hydroxy-phenethyl)-[2]piperidyl]-butan-2-ol
(2R,3R,6R,1E,3E,5E)-6-(deca-1,3,5-trienyl)-3-methoxy-1,2-dimethylpiperidine|N-methyl-6beta-(deca-1,3,5-trienyl)-3beta-methoxy-2beta-methylpiperidine|N-Methyl-6??-(deca-l,3,5-trienyl)-3??-methoxy-2??-methylpiperidine
(6Z,9Z,12Z,15Z)-2-aminooctadeca-6,9,12,15-tetraen-3-ol hydrochloride|obscuraminol A
venlafaxine
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D049990 - Membrane Transport Modulators CONFIDENCE Reference Standard (Level 1)
Padimate O
D020011 - Protective Agents > D011837 - Radiation-Protective Agents > D013473 - Sunscreening Agents C1892 - Chemopreventive Agent > C851 - Sunscreen D003879 - Dermatologic Agents D003358 - Cosmetics CONFIDENCE standard compound; INTERNAL_ID 1017; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10788; ORIGINAL_PRECURSOR_SCAN_NO 10787 CONFIDENCE standard compound; INTERNAL_ID 1017; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10902; ORIGINAL_PRECURSOR_SCAN_NO 10901 CONFIDENCE standard compound; INTERNAL_ID 1017; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10932; ORIGINAL_PRECURSOR_SCAN_NO 10927 CONFIDENCE standard compound; INTERNAL_ID 1017; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10957; ORIGINAL_PRECURSOR_SCAN_NO 10956 CONFIDENCE standard compound; INTERNAL_ID 1017; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10982; ORIGINAL_PRECURSOR_SCAN_NO 10981 DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; CONFIDENCE standard compound; INTERNAL_ID 1017; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; ORIGINAL_ACQUISITION_NO 10982; ORIGINAL_PRECURSOR_SCAN_NO 10981 CONFIDENCE standard compound; INTERNAL_ID 1017; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10805; ORIGINAL_PRECURSOR_SCAN_NO 10804 INTERNAL_ID 1017; CONFIDENCE standard compound; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10805; ORIGINAL_PRECURSOR_SCAN_NO 10804
(5R,E)-6-((8S,Z)-8-hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-2,5-dimethylhex-2-enal
(8S,Z)-6-((R,E)-2,5-dimethylhept-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol
(2R,5R)-2-(pent-4-en-1-yl)-5-pentyldecahydroquinoline
(5R,6R,8R,8aR)-6,8-dimethyl-5-(non-8-en-1-yl)octahydroindolizine
1-methyl-4-(non-8-en-1-yl)octahydro-2H-quinolizine
(3R,5S)-5-methyl-3-(non-8-en-1-yl)octahydro-1H-pyrrolo[1,2-a]azepine
PERHEXILINE
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C - Cardiovascular system > C08 - Calcium channel blockers > C08E - Non-selective calcium channel blockers D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Tetrabutylammonium chloride
D013501 - Surface-Active Agents > D003902 - Detergents
N,N-dimethyl-4-[(3-morpholin-4-ylpropylamino)methyl]aniline
1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
gamma-Linolenate
A linolenate that is the conjugate base of gamma-linolenic acid, arising from deprotonation of the carboxylic acid group.
alpha-Linolenate
A linolenate that is the conjugate base of alpha-linolenic acid, arising from deprotonation of the carboxylic acid group. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Crepenynate
A long-chain fatty acid anion and the conjugate base of crepenynic acid, arising from deprotonation of the carboxylic acid group.
(2R,3S)-1-[(7-Methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
9,11,14-Octadecatrienoate
Any octadecatrienoate having double bonds at positions 9, 11 and 14.
9,11,15-Octadecatrienoate
Any octadecatrienoate having double bonds at positions 9, 11 and 15.
6-ethyl-N-(2-methylbutyl)-1-oxo-2,3,3a,6,7,7a-hexahydroindene-4-carboxamide
Octadecatrienoate
A C18, straight-chain, unsaturated long-chain fatty acid anion and the conjugate base of its corresponding octadecatrienoic acid, formed by deprotonation of the carboxylic acid group.
1-deoxysphinga-6Z,9Z,12Z,15Z-tetraenine
A sphingoid that is 1-deoxysphinganine having cis-double bonds at positions 6, 9, 12, and 15.
2-methyl-5-(octa-1,3-dien-1-yl)-decahydroquinolin-3-ol
(9r,10r,11s,14s,15s,16r)-10-ethyl-14-methyl-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
(3r,5r,9ar)-5-methyl-3-(non-8-en-1-yl)-octahydro-1h-pyrrolo[1,2-a]azepine
3-methyl-5-(2-{octahydro-1h-pyrrolo[1,2-a]azepin-9-yl}propyl)-5h-furan-2-one
n-(2-methylpropyl)tetradeca-2,4,8-trienimidic acid
(2r)-1-[(2s,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]propan-2-ol
(2s,3s,4as,5s,8ar)-2-methyl-5-[(1e,3e)-octa-1,3-dien-1-yl]-decahydroquinolin-3-ol
16625-37-9
{"Ingredient_id": "HBIN001772","Ingredient_name": "16625-37-9","Alias": "NA","Ingredient_formula": "C17H27NO2","Ingredient_Smile": "CCC1C2CCCCN3C2C(CC3)C4C1OC(=O)C4C","Ingredient_weight": "277.4","OB_score": "14.30935308","CAS_id": "16625-37-9","SymMap_id": "SMIT10566","TCMID_id": "NA","TCMSP_id": "MOL009437","TCM_ID_id": "NA","PubChem_id": "177761","DrugBank_id": "NA"}
2,4,8-tetradecatrienoic acid; (2e,4e,8z)-form,2-methylpropylamide
{"Ingredient_id": "HBIN004274","Ingredient_name": "2,4,8-tetradecatrienoic acid; (2e,4e,8z)-form,2-methylpropylamide","Alias": "NA","Ingredient_formula": "C18H31NO","Ingredient_Smile": "NA","Ingredient_weight": "277.44","OB_score": "NA","CAS_id": "81427-14-7","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8900","PubChem_id": "NA","DrugBank_id": "NA"}
